Active components of Bupleurum chinense and Angelica biserrata showed analgesic effects in formalin induced pain by acting on Nav1.7

Saikosaponins: a review of pharmacological effects

(2018) Xiao-Qin Li et al.   JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH

A mutant of theButhus martensiiKarsch antitumor-analgesic peptide exhibits reduced inhibition to hNav1.4 and hNav1.5 channels while retaining analgesic activity

(2017) Yijia Xu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Na V 1.7 as a pain target – From gene to pharmacology

(2017) Irina Vetter et al.   PHARMACOLOGY & THERAPEUTICS

Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications

(2015) Manuel de Lera Ruiz et al.   JOURNAL OF MEDICINAL CHEMISTRY

Saikosaponin A protects against experimental sepsis via inhibition of NOD2-mediated NF-κB activation

(2015) HAIYAN ZHAO et al.   Experimental and Therapeutic Medicine

Sodium channel genes in pain-related disorders: phenotype–genotype associations and recommendations for clinical use

(2014) Stephen G Waxman et al.   LANCET NEUROLOGY

Saikosaponin-d inhibits proliferation of DU145 human prostate cancer cells by inducing apoptosis and arresting the cell cycle at G0/G1 phase

(2014) MIN YAO et al.   Molecular Medicine Reports

Attenuation of Neuropathic Pain by Saikosaponin a in a Rat Model of Chronic Constriction Injury

(2014) Xin Zhou et al.   NEUROCHEMICAL RESEARCH

Neurological perspectives on voltage-gated sodium channels

(2012) N. Eijkelkamp et al.   BRAIN

Distinct Nav1.7-dependent pain sensations require different sets of sensory and sympathetic neurons

(2012) Michael S. Minett et al.   Nature Communications

Ranolazine selectively blocks persistent current evoked by epilepsy-associated NaV1.1 mutations

(2010) Kristopher M Kahlig et al.   BRITISH JOURNAL OF PHARMACOLOGY

Subtype-selective targeting of voltage-gated sodium channels

(2009) Steve England et al.   BRITISH JOURNAL OF PHARMACOLOGY

Differential Block of Sensory Neuronal Voltage-Gated Sodium Channels by Lacosamide [(2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide], Lidocaine, and Carbamazepine

(2008) P. L. Sheets et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS